Key Drivers
- Cash Cushion
- Revenue Void
- Leverage Spike
AIAI Summary
ZBIO has shifted from a speculative biotech to an asset-backed story after Phase 3 success and BLA submission, but with no revenue and heavy cash burn, the stock now hinges on clean FDA approval and a strong launch before dilution and leverage erode the upside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Cushion
- •Revenue Void
- •Leverage Spike
ZBIO has strong liquidity with $718.5 million in liquid assets covering liabilities, but zero quarterly revenue, persistent losses, rising leverage, and heavy cash burn keep the fundamental outlook weak.
Price Behavior
Key Price Behavior Insights:
- •Breakout hold
- •Higher-high trend
- •Extension risk
ZBIO has surged in a strong uptrend over the last month, holding a breakout above $25.4-$25.9 and facing $28 resistance, but the rally is extended and now depends on support holding.
Sharp breakout from late
Sentiment & News
Key News Insights:
- •Investor outreach
- •Hiring activity
- •Insider confidence
Zenas BioPharma's June updates point to active investor outreach, hiring, and insider confidence, with no new clinical data disclosed.
The updates are modestly supportive and suggest ongoing management engagement, but they are unlikely to materially move the stock without clinical or pipeline catalysts
Similar Companies in Healthcare
Other companies in the same sector with AI ratings